No Data
No Data
No Data
No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $4 Price Target
Moomoo 24/7Apr 16 11:01 ET
Atossa Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 150.78% HC Wainwright & Co. → $4 Reiterates Buy → Buy 04/02/2024 150.78% HC Wainwright & Co. $4
BenzingaApr 16 10:59 ET
Express News | Atossa Therapeutics: Under Terms of Study, Co Will Conduct Study With Atossa & Eli Lilly and Co Each Responsible for Supplying Respective Study Drugs
Moomoo 24/7Apr 15 08:34 ET
Express News | Atossa Therapeutics and Quantum Leap Healthcare Announce I-Spy 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination With Abemaciclib (Verzenio®) in Women With Er+/Her2- Breast Cancer
Moomoo 24/7Apr 15 08:30 ET
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination With Abemaciclib (VERZENIO) in Women With ER+/HER2- Breast Cancer
The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) invasive breast cancer.
Globe NewswireApr 15 08:30 ET
Atossa Therapeutics Announces Breast Cancer Trial Evaluating Lead Asset in Combination With Eli Lilly Drug | NASDAQ:ATOS
Proactive InvestorsApr 15 05:18 ET
Bradley Taylor1 : what did this ken guy do?
No Data
No Data